Akebia Therapeutics (AKBA) said Thursday that the European Medicines Agency's Committee for Medicinal Products for Human Use recommended approval of Xoanacyl for treating elevated serum phosphorus and iron deficiency in adults with chronic kidney disease.
The company said Averoa, a biopharmaceutical company specializing in renal treatments, licensed the rights from Akebia to develop and market ferric citrate in the European Economic Area and certain countries in Europe and the Middle East.
The European Commission is expected to reach a final decision on Xoanacyl's approval within about two months, the biopharmaceutical company said.
Shares of Akebia were down more than 3% in recent Thursday trading.
Price: 1.87, Change: -0.06, Percent Change: -3.11
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。